RT info:eu-repo/semantics/article
T1 Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer
A1 Vargas, Teodoro
A1 Moreno Rubio, Juan
A1 Herranz, Jesús
A1 Cejas, Paloma
A1 Molina, Susana
A1 González-Vallinas Garrachón, Margarita
A1 Ramos, Ricardo
A1 Burgos, Emilio
A1 Aguayo, Cristina
A1 Custodio, Ana B.
A1 Reglero, Guillermo
A1 Feliu, Jaime
A1 Ramírez de Molina, Ana
K1 Cáncer colorrectal
K1 Síndrome metabólico
K1 Apolipoproteínas
K1 Biomarcador de pronóstico
K1 3207.13 Oncología
AB Studies have recently suggested that metabolic syndrome and its components increasethe risk of colorectal cancer. Both diseases are increasing in most countries, and the genetic association between them has not been fully elucidated. The objective of this studywas to assess the association between genetic risk factors of metabolic syndrome orrelated conditions (obesity, hyperlipidaemia, diabetes mellitus type 2) and clinicaloutcome in stage II colorectal cancer patients. Expression levels of several genes relatedto metabolic syndrome and associated alterations were analysed by real-time qPCR intwo equivalent but independent sets of stage II colorectal cancer patients. Using logisticregression models and cross-validation analysis with all tumour samples, we developeda metabolic syndrome-related gene expression profile to predict clinical outcome instage II colorectal cancer patients. The results showed that a gene expression profileconstituted by genes previously related to metabolic syndrome was significantly associated with clinical outcome of stage II colorectal cancer patients. This metabolic profilewas able to identify patients with a low risk and high risk of relapse. Its predictive valuewas validated using an independent set of stage II colorectal cancer patients. The identification of a set of genes related to metabolic syndrome that predict survival inintermediate-stage colorectal cancer patients allows delineation of a high-risk groupthat may benefit from adjuvant therapy and avoid the toxic and unnecessary chemotherapy in patients classified as low risk. Our results also confirm the linkage between.
PB Wiley Open Access
SN 1574-7891
YR 2014
FD 2014
LK http://uvadoc.uva.es/handle/10324/42589
UL http://uvadoc.uva.es/handle/10324/42589
LA eng
NO Molecular Oncology, 2014, vol. 8, n. 8, p.1469-1481
NO Producción Científica
DS UVaDOC
RD 30-jun-2024